The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
Open accessAbstract
BACKGROUND: Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their disease and current chemotherapy treatment only marginally increases survival. Novel therapies targeting receptor tyrosine kinases or activated oncogenes may improve outcome. Hence, it is necessary to stratify patients based on mutations in relevant oncogenes. Patients with non-muscle-invasive bladder cancer (NMI-BC) have excellent survival, however two-thirds develop recurrences. Tumor specific mutations can be used to detect recurrences in urine assays, presenting a more patient-friendly diagnostic procedure than cystoscopy. METHODOLOGY/PRINCIPAL FINDINGS: To address these issues, we developed a mutation assay for the simultaneous detection of 19 possible mutations in the HRAS, KRAS, and NRAS genes. With this assay and mutation assays for the FGFR3 and PIK3CA oncogenes, we screened primary bladder tumors of 257 patients and 184 recurrences from 54 patients. Additionally, in primary tumors p53 expression was obtained by immunohistochemistry. Of primary tumors 64% were mutant for FGFR3, 11% for RAS, 24% for PIK3CA, and 26% for p53. FGFR3 mutations were mutually exclusive with RAS mutations (p = 0.001) and co-occurred with PIK3CA mutations (p = 0.016). P53 overexpression was mutually exclusive with PIK3CA and FGFR3 mutations (p≤0.029). Mutations in the RAS and PIK3CA genes were not predictors for recurrence-free, progression-free and disease-specific survival. In patients presenting with NMI-BC grade 3 and MI-BC, 33 and 36% of the primary tumors were mutant. In patients with low-grade NMI-BC, 88% of the primary tumors carried a mutation and 88% of the recurrences were mutant. CONCLUSIONS/SIGNIFICANCE: The mutation assays present a companion diagnostic to define patients for targeted therapies. In addition, the assays are a potential biomarker to detect recurrences during surveillance. We showed that 88% of patients presenting with low-grade NMI-BC are eligible for such a follow-up. This may contribute to a reduction in the number of cystoscopical examinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Li, W., Zhu, T., & Guan, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405730200 · Cited by 77
RetractedRETRACTED ARTICLE: Targeting EGFR in bladder cancer
Villares, G. J., Zigler, M., Blehm, K., Bogdan, C., McConkey, D. J., Colin, D., & Bar‐Eli, M. (2007) · World Journal of Urology · doi:10.1007/s00345-007-0202-7 · Cited by 51
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“Cross-talk between the two signaling pathways can occur at several points and downstream they may converge on mammalian target of rapamycin kinase [70,71].”
BackgroundPhosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
TNM classification of malignant tumors, fifth edition (1997)
Sobin, L. H., & Fleming, I. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971101)80:9<1803::aid-cncr16>3.0.co;2-9 · Cited by 999
The health economics of bladder cancer: A comprehensive review of the published literature
Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B., & Hauser, R. (2003) · PharmacoEconomics · doi:10.1007/bf03262330 · Cited by 860
Histological Typing of Urinary Bladder Tumours
Mostofi, F. K., Davis, C. J., Sesterhenn, I. A., & Sobin, L. H. (1999) · Springer eBooks · doi:10.1007/978-3-642-59871-5 · Cited by 758
Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., Di Nicolantonio, F., Saletti, P., De Dosso, S., Mazzucchelli, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2466 · Cited by 739
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Babjuk, M., Oosterlinck, W., Sylvester, R., Kaasinen, E., Böhle, A., & Palou-Redorta, J. (2008) · European Urology · doi:10.1016/j.eururo.2008.04.051 · Cited by 723
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ
Pacold, M. E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 602
Clonal Origin of Bladder Cancer
Sidransky, D., Frost, P., Von Eschenbach, A., Oyasu, R., Preisinger, A. C., & Vogelstein, B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203123261104 · Cited by 532
Oncogenic PI3K and its role in cancer
Samuels, Y., & Ericson, K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198021.99347.b9 · Cited by 521
Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors
Billerey, C., Chopin, D., Aubriot-Lorton, M.-H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M.-P., Lefrere-Belda, M.-A., Lahaye, J.-B., Abbou, C. C., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64665-2 · Cited by 498
Self-citationRas Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase
Yan, J., Roy, S., Apolloni, A., Lane, A., & Hancock, J. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24052 · Cited by 477
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437
Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429
Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway
Yasoda, A., Komatsu, Y., Chusho, H., Miyazawa, T., Ozasa, A., Miura, M., Kurihara, T., Rogi, T., Tanaka, S., Suda, M., et al. (2004) · Nature Medicine · doi:10.1038/nm971 · Cited by 394
Rare cancer-specific mutations in PIK3CA show gain of function
Gymnopoulos, M., Elsliger, M.-A., & Vogt, P. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701005104 · Cited by 376
Tomlinson, D., Baldo, O., Harnden, P., & Knowles, M. (2007) · The Journal of Pathology · doi:10.1002/path.2207 · Cited by 363
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
Jebar, A. H., Hurst, C. D., Tomlinson, D. C., Johnston, C., Taylor, C. F., & Knowles, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208705 · Cited by 340
JOCHAM, D., WITJES, F., WAGNER, S., ZEYLEMAKER, B., van MOORSELAAR, J., GRIMM, M.-O., MUSCHTER, R., POPKEN, G., KöNIG, F., KNüCHEL, R., et al. (2005) · Journal of Urology · doi:10.1097/01.ju.0000169257.19841.2a · Cited by 336
Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis
Riley, G. F., Potosky, A. L., Lubitz, J. D., & Kessler, L. G. (1995) · Medical Care · doi:10.1097/00005650-199508000-00007 · Cited by 332
Ogino, S., Nosho, K., Kirkner, G. J., Shima, K., Irahara, N., Kure, S., Chan, A. T., Engelman, J. A., Kraft, P., Cantley, L. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6544 · Cited by 323
van Rhijn, B. W. G., Vis, A. N., van der Kwast, T. H., Kirkels, W. J., Radvanyi, F., Ooms, E. C. M., Chopin, D. K., Boevé, E. R., Jöbsis, A. C., & Zwarthoff, E. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.073 · Cited by 322
Self-citationGrossman, H. B., Gomella, L., Fradet, Y., Morales, A., Presti, J., Ritenour, C., Nseyo, U., Droller, M. J., & PC B302/01 Study Group (2007) · Journal of Urology · doi:10.1016/j.juro.2007.03.034 · Cited by 300
Bakkar, A., Wallerand, H., Radvanyi, F., Lahaye, J.-B., Pissard, S., Lecerf, L., Kouyoumdjian, J. C., Abbou, C. C., Pairon, J. ‐., Jaurand, M., et al. (2003) · PubMed · Cited by 270
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
Platt, F. M., Hurst, C. D., Taylor, C. F., Gregory, W. M., Harnden, P., & Knowles, M. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0898 · Cited by 251
van Rhijn, B. W. G., van der Kwast, T. H., Vis, A. N., Kirkels, W. J., Boevé, E. R., Jöbsis, A. C., & Zwarthoff, E. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2421 · Cited by 227
Self-citationLópez-Knowles, E., Hernández, S., Malats, N., Kogevinas, M., Lloreta, J., Carrato, A., Tardón, A., Serra, C., Real, F. X., & EPICURO Study Group Investigators (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1182 · Cited by 218
Hafner, C., López-Knowles, E., Luis, N. M., Toll, A., Baselga, E., Fernández-Casado, A., Hernández, S., Ribé, A., Mentzel, T., Stoehr, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705218104 · Cited by 209
Santarpia, L., El-Naggar, A. K., Cote, G. J., Myers, J. N., & Sherman, S. I. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1076 · Cited by 208
Molecular Pathogenesis and Diagnostics of Bladder Cancer
Mitra, A. P., & Cote, R. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092230 · Cited by 194
Lopez-Knowles, E., Hernandez, S., Malats, N., Kogevinas, M., Lloreta, J., Carrato, A., Tardon, A., Serra, C., & Real, F. X. (2006) · European Urology Supplements · doi:10.1016/s1569-9056(06)61338-9 · Cited by 173
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
Knowles, M. A., Platt, F. M., Ross, R. L., & Hurst, C. D. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9198-3 · Cited by 168
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma
Kozaki, K., Imoto, I., Pimkhaokham, A., Hasegawa, S., Tsuda, H., Omura, K., & Inazawa, J. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00343.x · Cited by 145
Hart, K. C., Robertson, S. C., & Donoghue, D. J. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.4.931 · Cited by 143
Signal Transduction Pathway of Human Fibroblast Growth Factor Receptor 3
Kanai, M., Göke, M. N., Tsunekawa, S., & Podolsky, D. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.10.6621 · Cited by 139
The clinical epidemiology of superficial bladder cancer
the members of the Dutch South-East Cooperative Urological Group, Kiemeney, L. A. L. M., Witjes, J., Verbeek, A. L. M., Heijbroek, R. P., & Debruyne, F. M. J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.147 · Cited by 131
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
Tomlinson, D. C., Hurst, C. D., & Knowles, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210399 · Cited by 128
Understanding urothelial carcinoma through cancer pathways
Schulz, W. A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21852 · Cited by 118
di Martino, E., L’Hôte, C., Kennedy, W., Tomlinson, D. C., & Knowles, M. A. (2009) · Oncogene · doi:10.1038/onc.2009.280 · Cited by 108
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer
Lotan, Y., Shariat, S. F., Schmitz‐Dräger, B. J., Sänchez‐Carbayo, M., Jankevičius, F., Racioppi, M., Minner, S. J. P., Stöhr, B., Bassi, P. F., & Grossman, H. B. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.11.004 · Cited by 105
Lurkin, I., Stoehr, R., Hurst, C. D., van Tilborg, A. A. G., Knowles, M. A., Hartmann, A., & Zwarthoff, E. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008802 · Cited by 102
Self-citationHurst, C. D., Zuiverloon, T. C. M., Hafner, C. M., Zwarthoff, E. C., & Knowles, M. A. (2009) · BMC Research Notes · doi:10.1186/1756-0500-2-66 · Cited by 97
Self-citationKassouf, W., Black, P. C., Tuziak, T., Bondaruk, J. E., Lee, S., Brown, G. A., Adam, L., Wei, C., Baggerly, K., Bar‐Eli, M., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.08.087 · Cited by 95
Kassouf, W., Dinney, C. P., Brown, G. A., McConkey, D. J., Diehl, J. A., Bar‐Eli, M., & Adam, L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1536 · Cited by 92
Molecular evolution of multiple recurrent cancers of the bladder
van Tilborg, A. A. G. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.20.2973 · Cited by 91
Agazie, Y. M., Movilla, N., Ischenko, I., & Hayman, M. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206798 · Cited by 88
Paterson, J., Li, Z., Wen, X., Masih‐Khan, E., Chang, H., Pollett, J. B., Trudel, S., & Stewart, A. K. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04814.x · Cited by 86
Ras and Phosphoinositide 3-Kinase: Partners in Development and Tumorigenesis
Ramjaun, A. R., & Downward, J. (2007) · Cell Cycle · doi:10.4161/cc.6.23.4996 · Cited by 80
MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
Masih‐Khan, E., Trudel, S., Heise, C. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017087 · Cited by 80
Targeted therapies in bladder cancer—an update
Black, P. C., Agarwal, P. K., & Dinney, C. P. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.05.011 · Cited by 80
Müller, C. I., Miller, C. W., Hofmann, W.-K., Gross, M. E., Walsh, C., Kawamata, N., Luong, Q. T., & Koeffler, H. P. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.04.011 · Cited by 78
Miyake, M., Ishii, M., Koyama, N., Kawashima, K., Kodama, T., Anai, S., Fujimoto, K., Hirao, Y., & Sugano, K. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162768 · Cited by 67
FGFR3andPIK3CAmutations are involved in the molecular pathogenesis of solar lentigo
Hafner, C. M., Stoehr, R., van Oers, J. M. M., Zwarthoff, E. C., Hofstaedter, F., Landthaler, M., Hartmann, A., & VOGT, T. M. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08963.x · Cited by 61
Self-citationFunctional differences between two classes of oncogenic mutation in the PIK3CA gene
Chaussade, C., Cho, K., Mawson, C., Rewcastle, G. W., & Shepherd, P. R. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.02.081 · Cited by 56
Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)
Pollard, C., Smith, S. C., & Theodorescu, D. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001407 · Cited by 52
Martinez-Torrecuadrada, J. L., Cheung, L. H., López-Serra, P., Barderas, R., Cañamero, M., Ferreiro, S., Rosenblum, M. G., & Casal, J. I. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0394 · Cited by 37
Cited by
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3212 · Cited by 808
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Lui, V. W. Y., Hedberg, M. L., Li, H., Vangara, B. S., Pendleton, K., Zeng, Y., Lu, Y., Zhang, Q., Du, Y., Gilbert, B. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0103 · Cited by 589
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
Metadata
- Authors
- Kompier, L. C., Lurkin, I., van der Aa, M. N. M., van Rhijn, B. W. G., van der Kwast, T. H., & Zwarthoff, E. C.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-11-03
- Volume
- 5
- Issue
- 11
- Pages
- e13821
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2011595291
- Cited by
- 315
- References
- 64
- FWCI
- 24.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.